

Yona Geffen PhD

Dr. Geffen joined Cytora leadership team as CEO in January 2025, bringing over two decades of experience in leading clinical and drug development in the biotechnology and pharmaceutical industry. Dr. Geffen served as CEO of Avraham Pharmaceuticals, a phase 2b clinical stage company developing drugs for Alzheimer's disease, and VP R&D of Gamida-cell, where she brought Omisirge[®], an allogeneic hematopoietic progenitor cell therapy to FDA approval. Prior to joining Cytora Yona served in different positions including VP R&D at Stem Cell Medicine, Vice President, Research and Validation at Compugen Ltd (NASDAQ: CGEN). Dr. Geffen holds a Ph.D from the Department of Immunology and Microbiology and an M.Sc. in business management, both from the Ben-Gurion University, Israel.